Clinical trials
Completed Glaucoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
796 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 4 |
| 2001 | 5 |
| 2002 | 7 |
| 2003 | 16 |
| 2004 | 13 |
| 2005 | 29 |
| 2006 | 34 |
| 2007 | 44 |
| 2008 | 36 |
| 2009 | 50 |
| 2010 | 49 |
| 2011 | 49 |
| 2012 | 37 |
| 2013 | 43 |
| 2014 | 51 |
| 2015 | 33 |
| 2016 | 32 |
| 2017 | 36 |
| 2018 | 36 |
| 2019 | 32 |
| 2020 | 23 |
| 2021 | 30 |
| 2022 | 20 |
| 2023 | 20 |
| 2024 | 19 |
| 2025 | 14 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 796 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alcon Research | 69 |
| Wills Eye | 34 |
| Allergan | 31 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 14 |
| Aerie Pharmaceuticals | 13 |
| Glaukos Corporation | 13 |
| Aristotle University Of Thessaloniki | 11 |
| Medical University of Vienna | 9 |
| Sensimed AG | 9 |
| University of Zurich | 9 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glaucoma | 796 |
| Ocular Hypertension | 237 |
| Glaucoma, Open-Angle | 183 |
| Cataract | 40 |
| Eye Diseases | 27 |
| Macular Degeneration | 20 |
| Hypertension | 19 |
| Diabetic Retinopathy | 16 |
| Low Tension Glaucoma | 16 |
| Exfoliation Syndrome | 12 |
Trials
Showing 1 to 25 of 796. Each trial links to its page on Pharma Observatory.
696 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.